Short course of letrozole before surgery reveals tumor hormone dependence
NCT ID NCT03747042
First seen Apr 18, 2026 · Last updated May 25, 2026 · Updated 4 times
Summary
This study involved 61 postmenopausal women with newly diagnosed, hormone-sensitive breast cancer. Participants took letrozole for 1 to 4 weeks before their standard surgery. The goal was not to treat the cancer directly, but to measure how much the tumor's growth slowed (using a marker called Ki67) to identify which cancers are highly hormone-dependent. This information helps doctors better understand the disease and may guide more personalized treatment in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER FEMALE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
Dallas, Texas, 75390, United States
Conditions
Explore the condition pages connected to this study.